Prognostic Impact of Minimal Pelvic Fluid in Locally Advanced Pancreatic Cancer: A Multicenter Retrospective Study

被引:0
|
作者
Lee, Jungnam [1 ]
Park, Jin-Seok [1 ,2 ]
Jeong, Seok [1 ,2 ]
Haeng, Don [1 ,2 ,3 ]
Lim, Jung-Hyun [1 ]
Cho, Soon Gu [4 ]
Kwon, Chang Il [5 ]
Hyun, Jong Jin
Choe, Jung Wan [6 ]
Cho, Jae Hee [7 ]
Jang, Sung Ill [7 ]
机构
[1] Inha Univ, Coll Med,Inha Univ Hosp, Dept Internal Med, Div Gastroenterol, Inchon, South Korea
[2] Inha Univ Hosp, Natl Ctr Efficacy Evaluat Dev Hlth Prod Targeting, Incheon, South Korea
[3] Utah Inha DDS & Adv Therapeut Res Ctr, Incheon, South Korea
[4] Inha Univ, Inha Univ Hosp, Coll Med, Dept Radiol, Incheon, South Korea
[5] CHA Univ, CHA Bundang Med Ctr, Digest Dis Ctr, Dept Internal Med, Seongnam, South Korea
[6] Korea Univ Ansan Hosp, Dept Internal Med, Ansan, South Korea
[7] Yonsei Univ, Gangnam Severance Hosp, Digest Dis Ctr,Coll Med, Dept Internal Med, Seoul, South Korea
关键词
Pancreatic neoplasms; computed tomography; survival; minimal pelvic fluid; ASCITES; MANAGEMENT; CHEMORADIOTHERAPY; ADENOCARCINOMA; CHEMOTHERAPY; GEMCITABINE; SURVIVAL; CT;
D O I
10.5152/tjg.2023.23309
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Minimal pelvic fluid (MPF) is occasionally encountered on computed tomography (CT) scans during the initial stag -ing of newly diagnosed pancreatic cancer. However, its clinical relevance has scarcely been studied. This study intends to explore the incidence of minimal pelvic fluid and its relevance in terms of survival in locally advanced pancreatic cancer (LAPC) patients.Materials and Methods: The medical records of patients with LAPC at 4 tertiary referral institutions were retrospectively reviewed from January 2005 to December 2015. Minimal pelvic fluid was defined as a fluid collection volume in the pelvic cavity of <100 mL as deter-mined by abdominal CT. The association between the presence of MPF and patient survival was evaluated.Results: A total of 59 patients (male:female, 33:26; median age, 68 years; range 46-82 years) with LAPC were enrolled. Of the 59 patients, 22.0% (n = 13) had MPF, and 78.0% (n = 46) had no pelvic fluid (NPF). Baseline clinical characteristics in the 2 groups, includ-ing extent of the tumor stage, extent of spread to the lymph nodes stage, and pattern of treatments, were not significantly different. However, median overall survival was significantly less in the MPF group [9.7 months, (95% CI, 5.9-13.5)] than in the NPF group as determined by the log-rank test [16.9 months, (95% CI, 9.3-24.5)] (P = .002), and univariate and multivariate analyses showed that the presence of MPF independently predicted a poor prognosis.Conclusion: The presence of MPF was found to be significantly associated with reduced survival and an independent poor prognostic biomarker in LAPC patients.
引用
收藏
页码:1249 / 1256
页数:79
相关论文
共 50 条
  • [1] Prognostic significance of preoperative CT-based sarcopenia in locally advanced rectal cancer: a multicenter retrospective study
    Zhu, Jiahong
    Gao, Yan
    Zhang, Chengjun
    Wu, Yanbo
    Wang, Qian
    Chen, Weizhi
    Lyu, Xiaohong
    Zhang, Xianglin
    Liu, Zhen
    Pan, Shinong
    BMC CANCER, 2025, 25 (01)
  • [2] Impact of chemoradiotherapy on the survival of unresectable locally advanced pancreatic cancer: a retrospective cohort analysis
    Wang, Zi-Meng
    Ma, Hong-Bin
    Meng, Yan
    BMC GASTROENTEROLOGY, 2023, 23 (01)
  • [3] Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX
    Choi, Young Hoon
    Lee, Sang Hyub
    You, Min Su
    Shin, Bang Sup
    Paik, Woo Hyun
    Ryu, Ji Kon
    Kim, Yong-Tae
    Kwon, Wooil
    Jang, Jin-Young
    Kim, Sun-Whe
    GUT AND LIVER, 2021, 15 (02) : 315 - 323
  • [4] FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan
    Matsumoto, Ippei
    Kamei, Keiko
    Omae, Katsuhiro
    Suzuki, Shuhei
    Matsuoka, Hidehiko
    Mizuno, Nobumasa
    Ozaka, Masato
    Ueno, Hideki
    Kobayashi, Satoshi
    Uesugi, Kazuhiro
    Kobayashi, Marina
    Todaka, Akiko
    Fukutomi, Akira
    PANCREATOLOGY, 2019, 19 (02) : 296 - 301
  • [5] Gastrointestinal Hemorrhage after Concurrent Chemoradiotherapy in Locally Advanced Pancreatic Cancer
    Lee, Kyong Joo
    Kim, Hee Man
    Jung, Joo Won
    Chung, Moon Jae
    Park, Jeong Youp
    Bang, Seungmin
    Park, Seung Woo
    Lee, Woo Jung
    Seong, Jin Sil
    Song, Si Young
    GUT AND LIVER, 2013, 7 (01) : 106 - 111
  • [6] Development and Validation of Multicenter Predictive Nomograms for Locally Advanced Pancreatic Cancer After Chemoradiotherapy
    Zhu, Xiaofei
    Liu, Wenyu
    Cao, Yangsen
    Su, Tingshi
    Zhu, Xixu
    Wang, Yiyang
    Ju, Xiaoping
    Zhao, Xianzhi
    Jiang, Lingong
    Ye, Yusheng
    Zhang, Huojun
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [7] Prolonged Neoadjuvant Therapy for Locally Advanced Pancreatic Cancer
    Eguchi, Hidetoshi
    Yamada, Daisaku
    Iwagami, Yoshifumi
    Gotoh, Kunihito
    Kawamoto, Koichi
    Wada, Hiroshi
    Asaoka, Tadafumi
    Noda, Takehiro
    Takeda, Yutaka
    Tanemura, Masahiro
    Sakai, Daisuke
    Satoh, Taroh
    Kudo, Toshihiro
    Isohashi, Fumiaki
    Mori, Masaki
    Doki, Yuichiro
    DIGESTIVE SURGERY, 2018, 35 (01) : 70 - 76
  • [8] Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer
    Weniger, Maximilian
    Moir, John
    Damm, Marko
    Maggino, Laura
    Kordes, Maximilian
    Rosendahl, Jonas
    Ceyhan, Gueralp O.
    Schorn, Stephan
    PANCREATOLOGY, 2020, 20 (06) : 1131 - 1138
  • [9] Effect of Radiotherapy in Neoadjuvant Treatment of Borderline Resectable and Locally Advanced Pancreatic Cancer
    Tang, Peng
    Zhang, Junfeng
    Zhou, Qiang
    Yi, Wenmin
    Wang, Huaizhi
    PANCREAS, 2025, 54 (03) : e246 - e254
  • [10] Failure patterns and outcomes of dose escalation of stereotactic body radiotherapy for locally advanced pancreatic cancer: a multicenter cohort study
    Zhu, Xiaofei
    Cao, Yangsen
    Su, Tingshi
    Zhu, Xixu
    Ju, Xiaoping
    Zhao, Xianzhi
    Jiang, Lingong
    Ye, Yusheng
    Cao, Fei
    Qing, Shuiwang
    Zhang, Huojun
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12